http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-045474-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-135 |
| filingDate | 2004-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f18397c170e170aa3ece3801ea135c29 |
| publicationDate | 2005-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-045474-A1 |
| titleOfInvention | DERIVATIVES OF USEFUL TIADIAZOLS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS |
| abstract | Pharmaceutical compositions and methods for the treatment of diseases, for example, neurodegenerative diseases such as Alzheimer's disease. Claim 1: A compound of formula (1), wherein the ring containing X, Y, U is an aromatic ring in which one of X, Y, U is an S and the other two of X, Y, U are N as shown are a group moiety of formula (2), where Z is selected from -C (= O) CHR1R2, -C (= S) CHR1R2, -C (= NR8) CHR1R2, -C (= O) C (= O) R1 and -S (O) 2-R1; R1 is selected from C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C1-20 alkoxy, C2-20 alkenoxy, C2-20 alkyloxy, C3-20 cycloalkyl, C4-20 cycloalkenyl, bi- or tricycloalkyl (C10 -20), bi- or tricycloalkenyl (C10-20), heterocycloalkyl (4-20 members), C6-20 aryl and heteroaryl (5-20 members); wherein R1 is optionally and independently substituted with one to six fluorine atoms or with one to three substituents independently selected from the group R1a; R1a is independently selected from -OH, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-6 alkoxy, C2-6 alkenoxy, C2-6 alkyloxy, -CF3, -OCF3, -Cl, -Br, -I, -CN, -NO2, -NR9R10, -C (= O) NR9R10, -SO2-NR9R10, -C (= O) R11, -S (O) n-R11, -C (= O ) OR12, C3-15 cycloalkyl, C4-15 cycloalkenyl, -bi- or tricycloalkyl (C5-11), -bi- or tricycloalkyl (C7-11), heterocycloalkyl (4-20 membered), C6-15 aryl, heteroaryl (5-15 members), C6-15 aryloxy and heteroaryloxy (5-15 members), wherein said cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryloxy and heteroaryloxy are each one independently and optionally substituted with one to three substituents independently selected from the group R1b; R1b is independently selected from -OH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenoxy, C2-6 alkyloxy, C1-6 hydroxyalkyl, -F, - Cl, -Br, -I, -CN, - NO2, -NR9R10, -C (= O) NR9R10, -C (= O) R11, -S (O) n-R11, C6-15 aryloxy and heteroaryloxy (of 5-15 members), wherein said alkyl, alkenyl and alkynyl are each independently and optionally substituted with one to six fluorine atoms or with one to two substituents independently selected from C1-4 alkoxy, or with a hydroxy group; R9 and R10 are selected in each instance independently of -H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, -CF3, -C (= O) R11, -S (O) n-R11, - C (= O) OR12, -C (= O) NR11R12, -SO2-NR11R12, - (C0-4 alkylene) - (C3-20 cycloalkyl), - (C0-4 alkylene) - (C4-8 cycloalkenyl), - (C0-4 alkylene) - (bi- or tricycloalkyl (C5-11)), - (C0-4 alkylene) - (bi- or tricycloalkyl (C7-11)), - (C0-4 alkylene) - (heterocycloalkyl ( 5-10 members)), (C0-4 alkylene) - (C6-10 aryl) and - (C0-4 alkylene) - (heteroaryl (5-10 members)), wherein said aryl, heteroaryl, alkyl, alkenyl and alkynyl are each independently and optionally substituted with one to six fluorine atoms or with one to two substituents independently selected from C1-4 alkoxy, or with a hydroxy group, and wherein said cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl and heteroaryl are each independently and optionally substituted with one to three substituents independently selected from -OH, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-6 alkoxy, C2-6 alkyloxy, C2-6 alkyloxy, C1-6 hydroxyalkyl, -F, -Cl, -Br, -I, -CN, -NO2, -CF3, -NH2, -C (= O) NH2, -SO2-NR9R10, C (= O) H and -C (= O) OH, wherein said alkyl, alkenyl substituents and alkynyl are, in addition, independently and optionally substituted with one to six fluorine atoms or with one to two substituents independently selected from C1-4 alkoxy, or with a hydroxy group; or NR9R10 may, in each instance, independently and optionally form a heterocycloalkyl moiety of four to ten ring members, said heterocycloalkyl moiety optionally containing one to two additional heteroatoms independently selected from N, O and S, and optionally containing one to three bonds doubles, wherein the carbon atoms of the NR9R10 heterocycloalkyl moiety are independently and optionally substituted with one to three substituents independently selected from -OH, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-6 alkoxy, alkenoxy C2-6, C2-6 alkyloxy, -F, -Cl, -Br, -I, -CF3, -NH2, -C (= O) NH2, -SO2-NH2, -C (= O) R11, -S (O) n-R11, (C0-4 alkylene) - (C6-10 aryl), (C0-4 alkylene) - (heteroaryl (5-10 members)), (C0-4 alkylene) - (C6 cycloalkyl) 10), and (C0-4 alkylene) - (heterocycloalkyl (5-10 member)), and wherein the substituent (C0-4 alkylene) - (heterocycloalkyl (5-10 member)), and nitrogen atoms of said rest or NR9R10 heterocycloalkyl are each independently and optionally substituted with a substituent independently selected from C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, -C (= O) NH2, -SO2-NH2, C (= O) R11, -S (O) n-R11, (C0-4 alkylene) - (C6-10 aryl), (C0-4 alkylene) - (heteroaryl (5-10 member)), (C0-4 alkylene) - (C6-10 cycloalkyl) and (C0-4 alkylene) - (heterocycloalkyl (5-10 members)), and wherein said alkyl, alkenyl and alkynyl substituents are furthermore independently and optionally substituted with one to six fluorine atoms , or with one to two substituents independently selected from C1-4 alkoxy, or with a hydroxy group; R11 and R12 are independently selected in each instance from C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, - (C0-4 alkylene) - (C3-15 cycloalkyl), - (C0-4 alkylene) - (cycloalkenyl) C4-8), - (C0-4 alkylene) - (bi- or tricycloalkyl (C5-11)), - (C0-4 alkylene) - (bi- or tricycloalkyl (C7-11)), - (C0- alkylene 4) - (C6-15 aryl), - (C0-4 alkylene) - (heterocycloalkyl (5-15 member)), and - (C0-4 alkylene) - (heteroaryl (5-10 member)), in where R11 and R12 are each independently substituted with one to three substituents independently selected from the group R1b; R2 -H, -OH, -NH2, -CH2OH, -OC (= O) CH3, -C (CH3) 2OH, -C (CH3) (CH2CH3) (OH), -C (OH) (C0-4 alkyl ) (C0-4 alkyl), - OC (= O) R4 and -OC (= O) OR4, wherein said -OC (= O) R4 and -OC (= O) OR4 may optionally be a prodrug of the corresponding OH of R2; R3 is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and - (C0-4 alkylene) - (C3-6 cycloalkyl), where when R3 is alkyl, alkenyl or alkynyl, R3 is independently substituted and optionally with a substituent independently selected from C1-4 alkoxy, -OH, -F and -S (C1-4 alkyl); R4 is selected from C1-4 alkyl, -CH (OH) (C1-4 alkyl), - CH (OH) (C5-6 aryl), -CH (OH) (heteroaryl (5-6 member)), - CH (OH) (C5-6 cycloalkyl), -CH (OH) (5-6 membered heterocycloalkyl); R5 is selected from -H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, -C (= O) (C1-4 alkyl), -C6-10 aryl, - heteroaryl (5-20 membered) , -SO2- (C6-10 aryl), -SO2- (heteroaryl (5-20 members)), -SO2-CH2- (C6-20 aryl) and -SO2-CH2- (heteroaryl (5-20 members) )); R7 is selected from -H, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C1-20 alkoxy, C2-20 alkenoxy, C2-20 alkyloxy, -F, -Cl, -Br, -I, - CN, -NO2, -OH, -CF3, -NR9R10, - (C1-11 alkylene) -NR9R10, -C (= O) NR9R10, -C (= O) R11, -CHO, -S (O) n- R11, -C (= O) OR12, - (C0-4 alkylene) - (C3-20 cycloalkyl), - (C0-4 alkylene) - (C4-20 cycloalkenyl), - (C0-4 alkylene) - (bi - or tricycloalkyl (C10-20)), - (C0-4 alkylene) - (bi- or tricycloalkenyl (C10-20)), - (C0-4 alkylene) - (heterocycloalkyl (3-20 member)), - (C0-4 alkylene) - (C6-15 aryl), - (C0-11 alkylene) - (C (= O) R11, - (C1-11 alkylene) - (COOH), - (C0-11 alkylene) - CHO, -SO2NR9R10, -S- (C1-20 alkylene) (C = O) OR8, -S- (C1-20 alkylene) -O- (C1-11 alkyl), -S- (C1-20 alkylene) - O- (C5-11 aryl), -SO2NR9R10, -S- (C1-20 alkylene) -NR9R10, - (C1-11 alkylene) -O- (C0-4 alkylene) -O- (C6-11 aryl), and - (C0-4 alkylene) - (heteroaryl (5-15 member)), wherein said heterocycloalkyl optionally contains from one to four double or triple bonds; wherein R7 is s optionally with one to six fluorine atoms or with one to three substituents independently selected from the group R1a; R8 is selected from -H and C1-6 alkyl; or, when Z is -C (= NR8) CHR1R2, R8 and R1 can form, together with the nitrogen and carbon atoms to which they are attached, a five to fourteen membered heteroaryl ring or a five to eight membered heterocycloalkyl ring, wherein said heteroaryl or heterocycloalkyl ring optionally contains one to two additional heteroatoms selected from N, O and S, and wherein said heterocycloalkyl ring optionally contains from one to three double bonds, and wherein said heteroaryl or heterocycloalkyl ring is optionally substituted with one to three substituents independently selected from the group R1b; n is 0, 1, 2, or pharmaceutically acceptable salts of said compounds. |
| priorityDate | 2003-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.